Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Ribbon symbolism Stories

2014-03-10 16:32:17

RICKMANSWORTH, England, March 10, 2014 /PRNewswire/ -- Lightpoint Medical announced today that the company and its surgical collaborators have received GBP1.7M ($2.8M) in grant funding from the UK's innovation agency, the Technology Strategy Board. The grant funding will be used for clinical trials of Lightpoint's intra-operative imaging technology in breast cancer and prostate cancer surgery. Collaborators on the clinical trials include Guy's and St Thomas' NHS Foundation...

Scientists Identify Potent Driver Of Metastasis
2014-03-10 12:44:42

The Wistar Institute Protein Correlates with Breast, Bladder, Melanoma, and Thyroid Tumors An international team of researchers led by scientists at The Wistar Institute have discovered and defined LIMD2, a protein that can drive metastasis, the process where tumors spread throughout the body. Their study, published in the March issue of the journal Cancer Research, defines the structure of LIMD2 and correlates the protein in metastatic bladder, melanoma, breast, and thyroid tumors....

2014-03-10 08:28:50

NEW YORK, March 10, 2014 /PRNewswire/ -- Lenox Hill Radiology, a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announces that 3D mammography, the latest innovation in breast cancer screening, is now available at its 79th Street location on the Upper West Side. Lenox Hill is among the first free-standing, full-service...

2014-03-08 23:01:58

Another meta-analysis has confirmed an increased risk of bladder cancer among diabetes patients who have taken the drug Actos (pioglitazone). Raleigh, NC (PRWEB) March 08, 2014 Cancer Monthly is reporting on a published study that appears to be more bad news for the manufacturers of the once-popular diabetes drug, Actos. The drug, also known as pioglitazone, was designed to help with glycemic control, but multiple studies have shown a connection between Actos and bladder cancer. In a...

2014-03-07 08:25:29

SYDNEY, March 7, 2014 /PRNewswire/ -- Viralytics Limited (ASX:VLA, OTC:VRACY) will present at two prominent U.S. healthcare investment conferences next week. CEO Dr Malcolm McColl will present on March 10 at the 26th Annual ROTH Investment Conference in Dana Point, California. The ROTH conference is one of the largest of its kind in the U.S. with approximately 3,000 attendees including 1,000 from the global investment community. On March 12 Dr. McColl will present at the Bernstein Emerging...

2014-03-06 23:24:30

Cianna Medical, Inc: Results could expand treatment options for more women with early-stage breast cancer. Aliso Viejo, CA (PRWEB) March 06, 2014 Cianna Medical, Inc., a women’s health company, today announced favorably low recurrence rates – even for younger women – as part of a retrospective analysis of 673 patients with invasive breast cancer treated with the SAVI® breast brachytherapy applicator. SAVI is a strut-based device that delivers a form of accelerated partial...

2014-03-06 23:23:25

Genomic Health Successfully Launched a Viral Educational Concept for Reaching People Touched by Breast Cancer Titled “Pass It On, Until Every Woman Knows” Indianapolis, IN (PRWEB) March 06, 2014 The Diagnostics Marketing Association (DxMA) announced today its 2013 Marketer of the Year: Genomic Health. This award recognizes diagnostic industry innovation by marketers in highlighting their company and/or products and will be presented during the annual DxMA Global Marketing Summit to...

2014-03-05 23:03:19

TNBC Comprises About 15-20 Percent of All Breast Cancer Diagnoses; Disproportionately Affects Women of African and Hispanic Descent New York, NY (PRWEB) March 05, 2014 Targeted therapies to treat triple negative breast cancer (TNBC), an aggressive, highly-metastatic disease that comprises about 20 percent of breast cancer incidences and which cannot be treated with conventional methods, may soon be realized, say researchers from the Icahn School of Medicine at Mount Sinai. Their study,...

2014-03-05 11:01:37

Johns Hopkins researchers identify set of genes that can be turned back on and potentially allow for more effective treatment Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body's immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment. Immune therapy for ovarian, breast and colorectal cancer — treatments that encourage the...

2014-03-05 10:59:39

Many breast cancer survivors experience fatigue and other debilitating symptoms that persist months to years after their course of treatment has ended. Now researchers at the Winship Cancer Institute of Emory University have found clues that may explain how these symptoms can linger. Chemotherapy, one of the major treatments for breast cancer, can leave a long-lasting epigenetic imprint in the DNA of breast cancer patients’ blood cells. That imprint is associated with biological signs of...